CACI International Inc ( CACI) M&A Call December 22, 2025 8:30 AM EST ...

ST. PAUL, MN / ACCESS Newswire / December 4, 2025 / Odyssey Transfer and Trust Company ("Odyssey" or the "Company"), a leading North American transfer agent and trust company that is scaling rapidly ...

(RTTNews) - Biotechnology company Q32 Bio, Inc. (QTTB) announced Monday it has sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics, Inc. (AKBA). ADX-097, the lead product candidate ...

Investing.com -- Q32 Bio Inc (NASDAQ:QTTB) stock surged 94% in premarket trading Monday after the clinical-stage biotechnology company announced the sale of its Phase 2 complement inhibitor, ADX-097, ...

Barely two months after emerging from stealth, Hivekind AI has announced the addition of a PR Agent to its existing suite of Agents. The new PR Agent complements the revenue-generating agents Hivekind ...

After a busy offseason, the Golden State Warriors have added several new pieces to their roster as they aim for another championship run. With Jonathan Kuminga’s contract situation finally settled, ...

Jake Fillery is an Evergreen Editor for Game Rant who has been writing lists, guides, and reviews since 2022. With thousands of engaging articles and guides, Jake loves conversations surrounding all ...

Gayle King showed off her signature colorful style in New York City on Feb. 18, donning a pair of bold purple Christian Louboutin boots to round out a vibrant wintertime ensemble. Gayle King wearing ...

Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.